Regulatory peptides technologies
We develop novel peptide therapeutics using a first in class peptide drug discovery platform. We address unmet medical needs for millions of patients suffering from mental and metabolic disorders.
Pipeline
We have invented an R&D platform to develop safe and effective regulatory peptides medications.
Step 1
Step 2
Step 3
Step 4
Step 5
Step 6
Proprietary peptide
discovery
Behavioral screening in zebrafish
Safety and
efficacy in rodents
Formal
preclinical
Clinical trials
Molecular target and mechanism of action
LCGA-17m16
Mental
GAD, PTSD,
Neurology
LCGM-10
Metabolic health
CHM-273
T2D,
Diabetic Nephropathy,
Aging
Reptide
IT platform for novel products
Robust efficacy
and pristine safety
LCGA-17m16 demonstrates both rapid and long-lasting anxiolytic and antidepressant activity without adverse effects through inhibition of a2d2 protein (subunit of VGCC receptors).
CHM-273 has a multimodal mechanism of action with Free fatty acid receptor 2 as a primary target. It decreases weight and appetite, normalizes glucose metabolism, and shows anti-inflammatory activity.
With the help of patent attorneys at Morgan, Lewis and Bockius LLP, we are building an extensive Intellectual property portfolio for our assets.
News
June, 2024 - Publication in Behavioral Brain Research: From land to water: “Sunken” T-maze for associated learning in cichlid fish.
https://doi.org/10.1016/j.bbr.2024.115077
February, 2024 - Publication in Behavioral Neuroscience: The novel peptide LCGM-10 attenuates metabotropic glutamate receptor 5 activity and demonstrates behavioral effects in animal models
https://doi.org/10.3389/fnbeh.2024.1333258
December, 2023 - We have been chosen as one of Hello Tomorrow's deep technology pioneers. From an impressive pool of 4,500 submissions across 120 countries, our project emerged as one of the most promising in the deep tech arena.
September, 2023 - Lactabico GmbH is among EIT Health Catapult 2023-24 30 semifinalists! Each year, the competition showcases Europe’s most promising life science and healthtech start-ups to leading experts and investors.
August, 2023 - Lactocore Group has become part of the Biolabs Heidelberg Accelerator!
Biolabs Heidelberg offers state-of-the-art facilities, expert mentorship, and a vibrant ecosystem that will accelerate our drug discovery and development efforts.
June, 2023 - Lactocore Group's CEO, Anton Malyshev, Featured in Tech.eu Interview!
We're excited to share that Anton Malyshev was recently interviewed by Cate Lawrence from Tech.eu - the premier online publication dedicated to the growing European technology ecosystems. Read the full interview to discover our innovative approaches and vision for the future.
June, 2023 - We are thrilled to share an insightful article by Sabine Elsässer that highlights our groundbreaking work with peptides. Discover why peptides are the cornerstone of our success and how they drive our mission forward: "Beharrlichkeit ist der Schlüssel" (article in German).
April, 2023 - Lactabico GmbH has won the "BioVaria Rising Startup Award" for groundbreaking work on developing peptide-based medications derived from milk for mental and metabolic disorders.
The award was presented at the BioVaria Startup Pitch & Partner Program, which featured ten handpicked start-ups in two categories. This year's event brought together over 270 innovators from academia and industry to promote partnerships for transferring life-science inventions into products. We are delighted to be recognized as a 'Rising Startup' and are grateful to the BioVaria team for attracting top-tier attendees.
To learn more about this event, please visit the BioVaria website.
December, 2022 - We are pleased to announce that we (Lactabico GmbH) have become part of the German Accelerator! We will strive to strengthen cooperation between US and German companies in developing innovative, effective, and safe peptide medicines!
2022 Conferences: American Diabetes Association's 82-nd Scientific Sessions; The EASD Annual Meeting 2022;
35-th ECNP Congress.
September, 2022 - Publication in Pharmaceutics: The novel Peptide Chm-273s Has Therapeutic Potential for Metabolic Disorders: Evidence from In Vitro Studies and High-Sucrose Diet and High-Fat Diet Rodent Models
https://doi.org/10.3390/pharmaceutics14102088
April, 2022 - Publication in Pharmaceuticals: Peptide LCGA-17 Attenuates Behavioral and Neurochemical Deficits in Rodent Models of PTSD and Depression
https://doi.org/10.3390/ph15040462
February, 2022 - 3rd patent application filled (CHM family)
2021 Conferences: 34-th ECNP Congress; 50-th Society for Neuroscience Annual Meeting.
August, 2021 - Publication in Front. Neurosci. In silico Screening and Behavioral Validation of a Novel Peptide, LCGA-17, With Anxiolytic-Like Properties
https://doi.org/10.3389/fnins.2021.705590
2020 Conferences: 33-rd ECNP Congress; BIO International Convention; Biotech Showcase.
April, 2020 - 2-nd patent application filled (LCGM family - https://patents.google.com/patent/WO2021211847A1/)
2019 Conferences: BIO International Convention; 48-th Society for Neuroscience Annual Meeting; 32-nd ECNP Congress.
March, 2019 - 1-st patent application filled (LCGA family - https://patents.google.com/patent/WO2020186155A2)
January, 2019 - Publication in Molecules: Rescoring Function for AutoDock Vina to Identify New Bioactive Molecules from Short Peptide Libraries.
https://doi.org/10.3390/molecules24020277
Team
Scientific and clinical advisors
Team is applying a rapid and cost-effective approach to early stage drug development, with guidance from leading scientific and medical experts. We welcome mutually beneficial collaborations with strategic pharma partners to bring our candidates closer to patients.
320 Nevada Street, Newton,
MA 02460, USA
Phone: +49 01624393615
(USA&Germany)
Lactocore Group
Headquarters: Monbijouplatz 3B, 10178 Berlin, Germany
info@lactocore.com
© Lactabico GmbH, Lactocore Inc, 2018-2024